Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
3
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
3
×
detroit top stories
fda
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
3
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
3
×
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
biogen
clinical trials
eli lilly
ipo
10x genomics
abbvie
accent therapeutics
aducanumab
alder biopharmaceuticals
allergan
What
fda
3
×
bio
medicines
new
roundup
won
activity
amgen
approval
approvals
august
biogen
biotech
busy
candidates
clamped
class
covid
days
decisions
delays
developed
developing
devices
drug
drugs
economic
fast
gets
head
including
ipo
isn’t
legacy
lot
migraine
news
nod
nods
opioid
Language
unset
Current search:
novartis
×
fda
×
" detroit blog main "
×
" san francisco blog main "
×
" boston top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines